Skip to main content
. Author manuscript; available in PMC: 2022 Jun 1.
Published in final edited form as: J Thorac Oncol. 2021 Feb 10;16(6):980–989. doi: 10.1016/j.jtho.2021.02.003

Table 1.

Demographic and clinical characteristics of NLST participants who underwent low dose computed tomography by prior history of cancer (PHC) status

Characteristic All
N=26,366
PHC
N=1,071
No PHC
N=25,295
p-value a
Age, years
Median (IQR) 60 (57-65) 62 (58-66) 60 (57-65) <.001
Gender, No. (%)
Male 15,583 (59.1) 289 (27.0) 15,294 (60.5) <.001
Female 10,783 (40.9) 782 (73.0) 10,001 (39.5)
Race, No. (%)
White 24,045 (91.2) 1,007 (94.0) 23,038 (91.1) 0.12
Black 1,171 (4.4) 36 (3.4) 1,135 (4.5)
Asian 547 (2.1) 14 (1.3) 533 (2.1)
American Indian/Alaska Native 90 (0.3) 2 (0.2) 88 (0.4)
Native Hawaiian/Pacific Islander 86 (0.3) 3 (0.3) 83 (0.3)
More than one race 326 (1.2) 8 (0.8) 318 (1.3)
Missing 100 (0.4) 1 (0.1) 100 (0.4)
Ethnicity, No. (%)
Hispanic or Latino 466 (1.8) 16 (1.5) 450 (1.8) 0.58
Non-Hispanic nor Latino 25,793 (97.8) 1,052 (98.2) 24,741 (97.8)
Missing 107 (0.4) 3 (0.3) 104 (0.4)
BMI, No. (%)
Underweight 226 (0.9) 12 (1.1) 214 (0.9) 0.004
Normal 7,427 (28.2) 354 (33.1) 7,073 (28.0)
Overweight 11,146 (42.3) 413 (38.6) 10,733 (42.4)
Obese 7,475 (28.4) 289 (27.0) 7,186 (28.4)
Missing 92 (0.4) 3 (0.3) 89 (0.4)
Median (IQR) 27 (24-31) 26 (24-30) 27 (24-31)
Educational Level, No. (%)
≤8th grade 358 (1.4) 13 (1.2) 345 (1.4) <0.001
9-11th grade 1,258 (4.8) 65 (6.1) 1,193 (4.7)
HS / GED 6,199 (23.5) 279 (26.1) 5,920 (23.4)
Post HS training 3,699 (14.0) 147 (13.7) 3,552 (14.0)
Assoc. degree/some college 6,127 (23.2) 268 (25.0) 5,859 (23.2)
Bachelor’s degree 4,455 (16.9) 157 (14.7) 4,298 (17.0)
Graduate school 3,737 (14.2) 121 (11.3) 3,616 (14.3)
Missing 533 (2.0) 21 (2.0) 512 (2.0)
Marital Status, No. (%)
Married or living as married 17,652 (66.9) 586 (54.7) 17,066 (67.5) <.001
Divorced 5,107 (19.4) 263 (24.6) 4,844 (19.2)
Widowed 1,961 (7.4) 144 (13.5) 1,817 (7.2)
Separated 334 (1.3) 16 (1.5) 318 (1.3)
Never married 1,236 (4.7) 62 (5.8) 1,174 (4.6)
Missing 76 (0.3) 0 76 (0.3)
Family History of Lung Cancer, b No. (%)
Yes 5,760 (21.8) 232 (21.7) 5,528 (21.9) 0.97
No 20, 606 (78.2) 839 (78.3) 19,767 (78.2)
Smoking Status, No. (%)
Former 13,686 (51.9) 578 (54.0) 13,108 (51.8) 0.18
Current 12,680 (48.1) 493 (46.0) 12,187 (48.2)
Pack-years
Median (IQR) 48 (39-66) 49 (40-66) 48 (39-66) 0.80
Comorbidities, c No. (%)
Median No. comorbidities (IQR) 1 (0-2) 1 (0-2) 1 (0-2) <.001
Asthma (adult) 1,630 (6.2) 104 (9.7) 1,526 (6.0) <.001
Asbestosis 274 (1.0) 9 (0.8) 265 (1.1) 0.50
Bronchiectasis 844 (3.2) 35 (3.3) 809 (3.2) 0.94
COPD 4,602 (17.5) 258 (24.1) 4,344 (17.2) <.001
Diabetes 2,555 (9.7) 106 (9.9) 2,449 (9.7) 0.76
Fibrosis 69 (0.3) 4 (0.4) 65 (0.3) 0.48
Heart disease or heart attack 3,410 (12.9) 152 (14.2) 3,258 (12.9) 0.11
Hypertension 9,268 (35.2) 407 (38.0) 8,861 (35.0) 0.04
Pneumonia 5,863 (22.2) 324 (30.3) 5,539 (21.9) <.001
Tuberculosis 276 (1.1) 13 (1.2) 263 (1.0) 0.61
Risk of lung cancer diagnosis (5-year risk per 1,000) d
Median (IQR) 11.7 (7.5-19.4) 13.3 (8.4-21.7) 11.7 (7.5-19.3) <.001
Risk of lung cancer death (5-year risk per 1,000) e
Median (IQR) 6.2 (3.7-10.9) 6.8 (4.1-12.3) 6.2 (3.7-10.9) <.001
a

Chi-square, Cochran-Armitage, Wilcoxon, and Kruskal-Wallis test statistics for differences by PHC status where appropriate, missing values not included.

b

Family history includes mother, father, brother, sister or biological child with a lung cancer diagnosis.

c

For comorbidities, number shown represents those who reported yes ever diagnosed prior to trial. COPD includes chronic bronchitis, COPD, and Emphysema; # comorbidities: a count of specific co-morbid conditions reported as ever diagnosed prior to trial: Asthma (adult), Asbestosis, Bronchiectasis, Chronic bronchitis, COPD, Diabetes, Emphysema, Fibrosis of the lung, Heart disease or heart attack, Hypertension, Pneumonia, Tuberculosis.

d

Among 1,000 people in the US with this risk-factor profile, this is the number who will be diagnosed with lung cancer if they do not attend screening (LCRAT). Based on taking the median of 10 imputed samples for those with missing covariate information.

e

Among 1,000 people in the US with this risk-factor profile, this is the number who will die from lung cancer if they do not attend screening.